The Market Doesnt Like What It Sees From Y-mAbs Therapeutics, Inc.s Revenues Yet As Shares Tumble 26
| YMAB Stock | USD 10.01 0.27 2.63% |
About 61% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Y-mAbs Therapeutics, Inc. shareholders that were waiting for something to happen have been dealt a blow...
Read at simplywall.st
 |
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Y MAbs is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
| CCCC | C4 Therapeutics | 9.28 | ||||
| STRO | Sutro Biopharma | 4.26 | ||||
| BDTX | Black Diamond | 2.09 | ||||
| MIRM | Mirum Pharmaceuticals | 1.82 | ||||
| EWTX | Edgewise Therapeutics | 1.15 | ||||
| GBIO | Generation Bio | 0.79 | ||||
| PCVX | Vaxcyte | 0.69 | ||||
| MRUS | Merus BV | 0.58 | ||||
| TVTX | Travere Therapeutics | 0.37 | ||||
| DAWN | Day One | 0.45 | ||||
| ERAS | Erasca | 0.67 | ||||
| RVMD | Revolution Medicines | 1.82 | ||||
| MRSN | Mersana Therapeutics | 2.75 | ||||
| LRMR | Larimar Therapeutics | 2.81 | ||||
| KRON | Kronos Bio | 2.86 | ||||
| ARQT | Arcutis Biotherapeutics | 2.89 | ||||
| ZNTL | Zentalis Pharmaceuticals | 3.05 | ||||
| PASG | Passage Bio | 3.80 | ||||
| SNDX | Syndax Pharmaceuticals | 3.98 | ||||
| BLUE | Bluebird Bio | 7.14 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |